Topical Treatment for Capillary Hemangioma of the Eyelid Using β-Blocker Solution

Guo, Suqin

doi:10.1001/archophthalmol.2009.370

Cited by 197 publications

(143 citation statements)

References 6 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Efficacy was assessed by performing blinded volume measurements at weeks 0, 1, 2, 3,4,8,12,16,20, and 24 and blinded investigator photograph scoring at weeks 0, 12, and 24. Safety was assessed by measuring heart rate and systolic and diastolic blood pressure at weeks 0, 1, 2, 3,4,8,12,16,20, and 24.…”

Section: What This Study Addsmentioning

confidence: 99%

“…Topical timolol solution is a nonselective b-adrenergic receptor inhibitor that was approved in 1978 for the treatment of glaucoma and has been safely used as first-line therapy for pediatric glaucoma for .30 years. 12,14 A number of case reports and case series have observed the efficacy of timolol maleate 0.5% gel for the treatment of IHs [15][16][17][18][19][20][21][22] ; however, concern has been raised regarding its safety. 12 This blinded, randomized, placebo-controlled study aims to begin to answer these questions relating to the safety and efficacy of topical timolol maleate 0.5% gel in the setting of small, superficial focal IHs in infants aged 5 to 24 weeks.…”

Section: What This Study Addsmentioning

confidence: 99%

“…12 In the studies of timolol maleate solution for the treatment of IHs, a case report of a 4-month-old girl developing blepharoptosis after treatment of a thinplaque IH on the upper eyelid with 0.5% timolol solution has been described. 16 The systemic absorption of timolol maleate gel formulation is considered to be significantly less than that of timolol maleate solution and hence has been favored in more recent studies. 33 With regard to the gel formulation, in a study in 73 individuals treated with timolol maleate 0.1% or 0.5% gel, 1 case of significant sleep disturbance necessitating treatment cessation has been reported as well as local site-ofapplication side effects such as burning, stinging, and irritant reactions.…”

Section: Safetymentioning

confidence: 99%

See 2 more Smart Citations

RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds

Chan¹,

McKay²,

Adams

et al. 2013

Pediatrics

131

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT:The systemic nonselective b-blocker propranolol hydrochloride is increasingly used as firstline management for infantile hemangiomas. Superficial nonulcerating lesions do not require systemic medications. Case series have suggested the efficacy of timolol; however, its safety has been questioned. WHAT THIS STUDY ADDS:This randomized controlled trial indicates that timolol maleate 0.5% gel is a well-tolerated, safe, and effective treatment of superficial infantile hemangiomas. abstract OBJECTIVE: Timolol maleate 0.5% gel is a safe and effective medication for treating superficial infantile hemangiomas (IHs) in infants with a median age of 9 weeks.METHODS: Forty-one infants who had superficial IHs without ulceration and not near mucosal surfaces were recruited and randomly assigned to placebo and treatment (timolol maleate 0.5% gel) groups. Efficacy was assessed by performing blinded volume measurements at weeks 0, 1, 2, 3,4,8,12,16,20, and 24 and blinded investigator photograph scoring at weeks 0, 12, and 24. Safety was assessed by measuring heart rate and systolic and diastolic blood pressure at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, and 24. RESULTS: Fifteen of the 19 infants receiving treatment and 17 of the 22 infants receiving placebo completed the study. Significant color change on the blinded photographic scores was noted at week 24 of the study (P = .003). There was a significantly higher proportion of treated IHs that reduced in size by .5% at weeks 20 and 24 (P , .02). The predicted proportion of IH volume change was also significantly less for treated IHs from week 16 onward when compared with placebo (P , .05). There was no significant variation in blood pressure and heart rate between the groups. CONCLUSIONS: Topical timolol maleate 0.5% gel with a maximum dose of 0.5 mg per day is a safe and effective option for small superficial IHs that have not ulcerated and are not on mucosal surfaces. Pediatrics

show abstract

Section: What This Study Addsmentioning

confidence: 99%

Section: What This Study Addsmentioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

See 1 more Smart Citation

RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds

Chan¹,

McKay²,

Adams

et al. 2013

Pediatrics

131

View full text Add to dashboard Cite

show abstract

“…Topical treatments can be used in small, superficial hemangiomas without life threatening. These treatments consist of agents such as intralesional steroids, topical steroids, imiquimode, and topical timolol [32][33][34][35] . Surgery in hemangiomas of periorbital region with cosmetic and organ dysfunction in selected cases, laser in cutaneous hemangiomas with a depth of not less than 1.2 mm, embolization in liver involvement and Kasabach-Meritt syndrome are the other treatment methods that can be applied [36][37][38] .…”

Section: Volume 59 • Numbermentioning

confidence: 99%

Clinical features and treatment results in children with hemangioma

2017

View full text Add to dashboard Cite

“…Tyrimai parodė, kad 0,5 proc. timololio maleato tepalas naudojamas 2 kartus per dieną 5 savaites, reikšmingai sumažina HA dydį, standumą ir pigmentaciją [22].…”

Section: Galvos Ir Kaklo Srities Hemangiomų Gydymo Būdų Apžvalgaunclassified

Šiuolaikinis Galvos Ir Kaklo Srities Hemangiomų Gydymas

Šiupšinskienė¹,

Pašvenskaitė

Norkienė³

2017

Public Health

View full text Add to dashboard Cite

Raktažodžiai: hemangioma, galva ir kaklas, konservatyvus gydymas, chirurginis gydymas, propranololis. SantraukaHemangioma -tai dažniausiai pasireiškiantis nepiktybinis navikas galvos ir kaklo srityje. Iki šiolei pirmo pasirinkimo vaistas gydant šios srities hemangiomas buvo peroraliniai kortikosteroidai, tačiau nauji tyrimai pagrindžia β blokatorių veiksmingumą. Straipsnyje aptariami šiuolaikiniai galvos ir kaklo hemangiomų konservatyvaus gydymo principai bei intervencinės procedūros. Pristatomi dviejų suaugusių moterų, kurioms diagnozuotos hemangiomos ryklės bei liežuvio šaknies srityse, klinikiniai atvejai. ĮvadasHemangioma (HA) -tai kraujagyslinis nepiktybinis navikas, dažniausiai pasireiškiantis antrą -dešimtą gyvenimo savaitę 2,5 proc. naujagimių [1]. HA atsiranda dėl per greito kraujagyslių išvešėjimo, kuris neatitinka audinio ir organo vaskuliarizacijos poreikio ir nėra pateisinamas fiziologiškai. Dažniau HA pastebimos moterims (moterų ir vyrų santykis=2:1) [2].Nors HA dažniausiai pasireiškia vaikams, jos gali atsirasti ir vyresniame amžiuje -paprastai vyresniems nei 40 metų pacientams [3]. HA, pasireiškiančios suaugusiems, yra mažesnės palyginus su vaikų, tačiau pasitaiko ir didelių, susitelkusių į grupeles HA atvejų. Suaugusiųjų HA atsiradimo priežastis nėra aiški -keletas teorijų teigia genetinę kilmę ar HA atsiradimą dėl nuolat dirginančių cheminių medžiagų [3].Iki šiolei nusistovėjusios ir vieningos HA klasifikacijos nėra. Klinikiniame darbe priimtiniausia yra histologinė -susiformavimo klasifikacija, pagal kurią HA skirstomos į keletą kategorijų: 1) pagal kraujagyslinę sandarą -į kapiliarines, kavernines, arteriovenines; 2) pagal atsiradimo laiką -į įgimtas ir infantilines (1 lentelė) [4][5][6][7]. Infantilinė

show abstract

Topical Treatment for Capillary Hemangioma of the Eyelid Using β-Blocker Solution

Cited by 197 publications

References 6 publications

RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds

RCT of Timolol Maleate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds

Clinical features and treatment results in children with hemangioma

Šiuolaikinis Galvos Ir Kaklo Srities Hemangiomų Gydymas

Contact Info

Product

Resources

About